Proceduresof Choice in Renal Nuclear Medicine

Total Page:16

File Type:pdf, Size:1020Kb

Proceduresof Choice in Renal Nuclear Medicine Proceduresof Choice in Renal Nuclear Medicine M. Donald Blaufox Department ofNuclear Medicine, Albert Einstein College ofMedicine/Montefiore Medical Center, Bronx, New York radionuclide method for measuring residual urine, which The uronephrologicapplicationsof nuclear medicine have was described more than 20 years ago, has not achieved reached a stage of maturity where procedures of choice for general use and may now be largely obsolete. Testicular manyspecificclinicalproblemscan be identified.This review imaging is established in genitourinary imaging while the attempts to achieve this aim as objectively as possible. It application of radionuclides to studies of patients with must be emphasizedthat the opinionsexpressedhere are impotence and related diseases is rapidly moving toward those of the author and in many areas there may be a lack of clinical practice and will likely expand this area of use in consensus. the future. J NuclMed 1991;32:1301—1309 The specific pathologic conditions in which nuclear medicine may play a role are listed in Table 2. In reviewing procedures of my choice in renal nuclear medicine, it is necessary also to evaluate these procedures he most important concept in studying the kidney is in relation to radiographic and other diagnostic imaging a recognition of the intimate relationship between struc procedures. The complementary modalities to be consid ture and function. Although procedures which are primar ered are ultrasound, urography, angiography, and corn ily functional and procedures dependent on imaging are puted tomography (CT). At this time, there are few data discussed separately here, no renal study can be evaluated that would support the utilization of magnetic resonance properly without considering its physiologic basis. Table 1 imaging (MRI) in the routine clinical evaluation of the lists the major radionuclide procedures available in uro kidneys and urinary tract. This area ofapplication of MRI nephrology. has been a great disappointment so far, but continues to Among the clearance methods, the continuous infusion be an area of active investigation. technique has been and continues to be a major method for investigational studies where accurate and precise RADIOPHARMACEUTICALSFOR RENAL STUDIES measurements of renal function are needed. The use of The radiopharmaceuticals that have been used for kid continuous infusion clearance in clinical practice is limited ney studies are shown in Figure 1. and will not be discussed here. The single injection clear ance methods offer the great advantages ofsimplicity, ease Glomerular Filtration Rate of performance, low radiation dose, and reasonable accu The radionuclide agent of choice for an extremely ac racy. curate measurement of the glomerular filtration rate Radiorenography has evolved into a complex technique. (GFR) is 51Cr-EDTA(1). This agent is not available in the Captopril renography is being used with increasing fre U.S., but it is widely used in Europe. The clearance of 51C- quency while exercise stress renography may prove to be EDTA is virtually identical with the clearance of inulin, of value in the future. Among the pharmaceuticals for therefore, it is a true GFR marker. In the U.S., 1311 renal imaging, 99mTc..glucoheptonate and @mTc@DMSAiothalamate has been used in its place. Technetium-99m- have very different mechanisms of renal handling than DTPA has a clearance rate approximately 5% less than 99mTcDTpA (excreted by glomerular filtration), and that of inulin (2), which usually is an acceptable error in 99mTcMAG and ‘311-hippuran(excreted primarily by tu clinical practice. The error of serum creatinine is in the bular secretion). Technetium-99m-MAG3 has been ap range of 10% or 15% in estimating GFR and may be proved recently by the FDA and is available for routine greater in renal failure. Technetium-99m-DTPA yields an applications, although pediatric use of this agent has not estimate of the GFR within 5% of the true GFR. It is yet received approval. inexpensive, has a low radiation dose, and, most impor The radionuclide cystogram has achieved widespread tantly, it can be usedfor renal imaging, making it the GFR application in the evaluation of ureterovesical reflux. The agent ofchoice overall in clinicalnuclear medicine practice. TubularSecretion Received Nov. 14, 1990; revision accepted Mar. 27, 1991. For reprintsContact:M.DonaldBlaufox,MD,PhD,AlbertEinsteinCollege Iodine-131-hippuran is currently the agent of choicefor of Medicine, 1300 Morris Park Ave., Bronx, New York 10461. estimating effective renalplasmafiow (ERPF). Iodine-123- Procedure Choices in Renal Nuclear Medicine •Blaufox 1301 TABLE I TUSULARRE8ORpflCH ..@ .. OLOMERULARFILTRAT1ON @ Lkonephrologic Procedures in Nudear Medicine @To@schniS@• . I “@“c@ @ “•,_.‘@‘I4S8A ___ 1. ClearanceMethods 5. RadiOnUclidecystogram I I c __J“cl'EDyA A. Continuousinfusion A. Residualurine \ — “0LfrOTPA B. Singleinjection B. Ureterovesicalreflux I I @To@OT@ C. Simplifiedsingleinjec 6. Scintiphotography I @@4-OA@@s tion A. lndMdualrenalfunction ri D. Invivocamera tech 1. 131l_,lssl@hippuran CORTEX niques 2. @“Tc-DTPA Tueu@ReEcRE@Ow. 2. Radioimmunoassay 3. @Tc-MAG3 EFFECTRERENALPLAMAFLOW 3H.‘@C@PAH @ A. Angiotensin B. Individualrenalmass IR,@ B. ReninactMty 1. @Tc-DMSA C. 2. @“Tc-glucoheptonate 3. Radiorenography C. Perfusionimaging A. @“1c-DTPA 1. Anylow-dose @rcagent B. ‘31―@I-hippuran D. Morphology Tueu@RRXATmN. C. 1. Renalmassagents MEDULLA @MOR@OLOOv D. Miscellaneous 7. Renal blood flow 4. Body spaces 8. Genitalimaging A. Penilebloodflow B. Testicularperfusion hippuran has a lower radiation dose, and so it is theoreti FIGURE1. Graphicdepictionof the areasof the nephron cally preferable to 1311,but because ofcost limitations and where various radiopharmaceuticalsare handled. Those phar a short shelf life, the 1311agent is the most practical for maceuticalsthat areconsideredto beagentsof choiceareshown measuring ERPF. Technetium-99m-MAG3, which has inbold. only been available for a relatively brief time in the U.S., may assume a major role in evaluating tubular secretion. MAG3 is significantly different from hippuran in that Static Imaging Agents MAG3 apparently clears at a rate lower than ‘31I-hippuran Technetium-99m-DMSA and @mTc@glucoheptonateare (about 80%) because it is not filtered by the glomerulus the two major agents available for renal parenchymal (4). Although it has lower clearance values, MAG3 is taken imaging. These two radiopharmaceuticals are very differ up in very high quantities, gives excellent renal images, ent. A significant portion ofglucoheptonate is ifitered (5), and has moved rapidly into routine practice. The small so that in patients with urinary tract obstruction, the difference in excretion characteristics may be of value in accumulation of glucoheptonate in the collecting system some situations where it is desirable to evaluate pure can present a problem in interpreting parenchymal images. tubular secretion. Hepatic excretion ofMAG3 is a problem In patients without urinary tract obstruction, the filtered that may interfere with its use in single injection clearances component is not a problem and it can be advantageous at low levels of renal function. Clearance techniques that in providing additional information about the collecting include urine collection avoid this problem. system. Technetium-99m-DMSA is handled by a very different TABLE2 excretory mechanism (6). Glucoheptonate shares the en NuclearMedicinein GenitounnaryDisease zyme system for para-amino-hippuric acid and 131I-hip Acute renal failure puran in the proximal tubules, while 99mTcDM5A is cx Chronicrenalfailure creted by a different process. It is concentrated to a greater Con@ anomahes extent (about 40% ofit is accumulated in the kidneys) and Epididymitis as a result 99mTcDM5A delivers a much higher radiation Impotence dose (per MCi administered) to the kidney than 99mTc@ MassLesions Pyelonephritis glucoheptonate. If a renal perfusion study is needed in Quantitationof renalfunction conjunction with a static imaging study, @mTc@glucohep RenalperfusionabnOrmalities tonate is suitable because of the lower radiation dose. Renaltrauma Technetium-99m-DMSA should not be used for flow stud Renovascularhypertension ies, but it is an ideal agent for extremely detailed renal Residualurine Testiculartorsion cortical images. The best way to minimize radiation dose Transplantation and perform a flow study in patients in whom perfusion Ureteralvesicalreflux imaging is needed in concert with static imaging is to do a Urinarytractobstruction flow study with @mTc@DTPAfollowedby a static study with Varicocoele 99mTcglucoheptonate, or if very fine resolution is needed, I 302 TheJournalof NuclearMedicine•Vol.32 •No.6 •June1991 followed by 99mTcDMSA Quantitative separated renal ERPF: in vitro 1 sample method ( fl ) vs. in vitro 2 sample method (I) function studies may be performed with DMSA. Many 800 centers use a single dose of glucoheptonate for the perfu @ 700 sion and imaging study. A number of centers use gluco @ heptonate instead of DMSA for quantitative imaging. 600 • • •••• • S . • Gallium may be considered as a renal agent when used @5oo. S @ in studying pyelonephritis or renal abcess. Monoclonal 400 antibodies and indium-labeled white cells have not proved practical for renal imaging and are not discussed here, E @-.-—-.--@ y(fl)—O.850X(I)-73 @ although they are still being actively investigated. 200 n-41 @ CLEARANCEMETHODS I
Recommended publications
  • Pictures of Central Venous Catheters
    Pictures of Central Venous Catheters Below are examples of central venous catheters. This is not an all inclusive list of either type of catheter or type of access device. Tunneled Central Venous Catheters. Tunneled catheters are passed under the skin to a separate exit point. This helps stabilize them making them useful for long term therapy. They can have one or more lumens. Power Hickman® Multi-lumen Hickman® or Groshong® Tunneled Central Broviac® Long-Term Tunneled Central Venous Catheter Dialysis Catheters Venous Catheter © 2013 C. R. Bard, Inc. Used with permission. Bard, are trademarks and/or registered trademarks of C. R. Bard, Inc. Implanted Ports. Inplanted ports are also tunneled under the skin. The port itself is placed under the skin and accessed as needed. When not accessed, they only need an occasional flush but otherwise do not require care. They can be multilumen as well. They are also useful for long term therapy. ` Single lumen PowerPort® Vue Implantable Port Titanium Dome Port Dual lumen SlimPort® Dual-lumen RosenblattTM Implantable Port © 2013 C. R. Bard, Inc. Used with permission. Bard, are trademarks and/or registered trademarks of C. R. Bard, Inc. Non-tunneled Central Venous Catheters. Non-tunneled catheters are used for short term therapy and in emergent situations. MAHURKARTM Elite Dialysis Catheter Image provided courtesy of Covidien. MAHURKAR is a trademark of Sakharam D. Mahurkar, MD. © Covidien. All rights reserved. Peripherally Inserted Central Catheters. A “PICC” is inserted in a large peripheral vein, such as the cephalic or basilic vein, and then advanced until the tip rests in the distal superior vena cava or cavoatrial junction.
    [Show full text]
  • Nuclear Medicine for Medical Students and Junior Doctors
    NUCLEAR MEDICINE FOR MEDICAL STUDENTS AND JUNIOR DOCTORS Dr JOHN W FRANK M.Sc, FRCP, FRCR, FBIR PAST PRESIDENT, BRITISH NUCLEAR MEDICINE SOCIETY DEPARTMENT OF NUCLEAR MEDICINE, 1ST MEDICAL FACULTY, CHARLES UNIVERSITY, PRAGUE 2009 [1] ACKNOWLEDGEMENTS I would very much like to thank Prof Martin Šámal, Head of Department, for proposing this project, and the following colleagues for generously providing images and illustrations. Dr Sally Barrington, Dept of Nuclear Medicine, St Thomas’s Hospital, London Professor Otakar Bělohlávek, PET Centre, Na Homolce Hospital, Prague Dr Gary Cook, Dept of Nuclear Medicine, Royal Marsden Hospital, London Professor Greg Daniel, formerly at Dept of Veterinary Medicine, University of Tennessee, currently at Virginia Polytechnic Institute and State University (Virginia Tech), Past President, American College of Veterinary Radiology Dr Andrew Hilson, Dept of Nuclear Medicine, Royal Free Hospital, London, Past President, British Nuclear Medicine Society Dr Iva Kantorová, PET Centre, Na Homolce Hospital, Prague Dr Paul Kemp, Dept of Nuclear Medicine, Southampton University Hospital Dr Jozef Kubinyi, Institute of Nuclear Medicine, 1st Medical Faculty, Charles University Dr Tom Nunan, Dept of Nuclear Medicine, St Thomas’s Hospital, London Dr Kathelijne Peremans, Dept of Veterinary Medicine, University of Ghent Dr Teresa Szyszko, Dept of Nuclear Medicine, St Thomas’s Hospital, London Ms Wendy Wallis, Dept of Nuclear Medicine, Charing Cross Hospital, London Copyright notice The complete text and illustrations are copyright to the author, and this will be strictly enforced. Students, both undergraduate and postgraduate, may print one copy only for personal use. Any quotations from the text must be fully acknowledged. It is forbidden to incorporate any of the illustrations or diagrams into any other work, whether printed, electronic or for oral presentation.
    [Show full text]
  • Renovascular Hypertension
    z RENOGRAM INIS-mf —11322 RENOVASCULAR HYPERTENSION G.G. Geyskes STELLINGEN Behorende bij het proefschrift THE RENOGRAM IN RENOVASCULAR HYPERTENSION door G.G. Geyskes \ "n. it f 1 VII Het captopril renogratn kan de diagnostische PTA zoals door Maxwell Paranormale geneeskunde bij patiënten met hypertensie heeft meer bepleit vrijwel vervangen. subjectieve dan objectieve effecten. M.H. Maxwell. A.V. Walu. Hyptritnsion 1914.6:589-392. II VIII Bij dubbelzijdige nierarteriestenose geeft ncfrectomie van een kleine Het lijkt mogelijk de ontwikkeling van diabetische nefropathie af te nier in combinatie met PTA van de contralaterale nier vaak verbetering remmen door medicamenteuze antihypertensieve therapie, speciaal met van de totale nierfunktie. converting enzyme inhibitors. Ill IX Onderdrukking van de PRA is een antihyperteniief mechanisme van Het roken van sigaretten kan een oorzaak van renovaculaire hyperten- betaMokkers. sie zijn. G.G. Geyskts. J. Vos. P. Boer. E.J. Dorhoul Mets. Lmcei 1976:1049-1051. CE. Grimm el al. Nrphron 1986. 44 SI: 96-100. IV Contractie van het extracellulair volume is een antihyperteniief mecha- Het metaiodobenzylguanidine scintigram is een aanwinst bij de diag- nisme van diuretka. nostiek van het feochromocytoom. De opname van deze stof kan ook U.A.M. van Seht». G.G. Geyskti. J.C. Hom. El Dorhoul Mees. therapeutische consequenties hebben. CKn Phorm è Vier 1986. 39:6044, XI Bij veroordeling voor een /.waar misdrijf kan men 't best een levenslange Het clonidine withdrawal syndroom is een vrij sterke contraindicatie tegen het gebruik van dit antihyptttensivum. strul geven die verkort wordt bij verbetering van de mentaliteit. G.G. Geyskts. P. Boer. E.J.
    [Show full text]
  • Home Dialysis
    Have you thought about DIALYSIS at There is more than one HOME? way to treat kidney failure. Choosing your treatment is about helping you live your life. GETTING INVOLVED REALLY MATTERS You’ll feel more in charge if you take an active role in the decision. Your kidney team should tell you about all treatment options and the pros and What are the first steps? cons of each. But you make Learn about the different options for treatment of kidney failure. the choice based on your n Talk to the professionals who are treating you. needs, lifestyle, medical n Ask questions: conditions, and current • What treatments are done at home? level of kidney function. In • Am I eligible for home treatments? • How will my choice of treatment affect my order to make this decision, health and lifestyle? you need to learn about all • At this point in my kidney disease, is one choice better than another? the treatments. • Will one treatment better protect my remaining kidney function? Which one? 2 Where can you learn about your options? When you have kidney disease, a team of professionals (your kidney team) will help you understand how your choice will affect your life. Ask questions to be sure what the right option is for you. Discuss the things that are most important to you and any concerns or worries you may have. Visit the National Kidney Foundation website at www.kidney.org for helpful resources. You can also call the NKF Cares patient help line toll-free at 1.855.NKF.CARES (1.855.653.2273) or email [email protected].
    [Show full text]
  • An Interesting Presentation of Invasive Bladder Carcinoma As Pseudo
    An interesting presentation of invasive bladder carcinoma as pseudo renal failure Uma apresentação interessante do carcinoma invasivo de bexiga como pseudo insuficiência renal ABSTRACT RESUMO Authors Ascites and oliguria with an increasing Ascite e oligúria com um nível crescente Ashwin Shekar1 serum creatinine level are often observed de creatinina sérica são frequentemente 1 Anuj Dumra in patients with acute renal failure. observadas em pacientes com insuficiência 1 Dinesh Reddy However, these symptoms are also renal aguda. Entretanto, esses sintomas 1 Hardik Patel noted in individuals with intraperitoneal também são notados em indivíduos com urinary leakage and can be mistaken for extravasamento urinário intraperitoneal acute renal failure. This rise in creatinine e podem ser diagnosticados como lesão 1 Sri Sathya Sai Institute of Higher in such patients is called pseudo renal renal aguda erroneamente. Este aumento Medical Sciences, Department of Urology, Prashantigram, failure and it happens by a process of de creatinina em tais pacientes é chamado Puttaparthi, Andhra Pradesh reverse peritoneal dialysis. In literature, de pseudo insuficiência renal e ocorre por 515134, India. the most commonly described condition um processo de diálise peritoneal reversa. that leads to this clinical picture is Na literatura, a condição mais comumente following a spontaneous or missed descrita que leva a este quadro clínico se dá bladder perforation. We, herein, report após uma perfuração vesical espontânea ou a case of carcinoma of the bladder that perdida. Relatamos aqui um caso de carcinoma presented with features resembling acute de bexiga que apresentou características renal failure, which later turned out to be semelhantes à insuficiência renal aguda, e pseudo renal failure due to intraperitoneal mais tarde se revelou uma pseudo insuficiência urinary extravasation from a forniceal renal devido a extravasamento urinário rupture.
    [Show full text]
  • Dynamic Renogram
    Dynamic Renogram What is a dynamic renogram scan? measure the number of gamma ray counts over time and plot the uptake, excretion and clearance Water soluble substances are predominantly data on a graph to form an objective analysis. cleared from the body via the kidneys. The rate at which waste products are cleared is a reflection of But injecting different chemical tracers that are the efficiency of the kidney and referred to as excreted in different ways by the kidney, we can kidney function. infer information about different aspects of kidney function i.e. DTPA is filtered and used to assess Many conditions can affect this function. Without filtration function; MAG3 is secreted by the kidney being able to clear waste products the body would tubular cells and used to assess tubular function eventually deteriorate and eventually one organ (and indirectly assess filtration function) and OIH system after another with begin to fail. It is combines both of these and allows us the assess a imperative that we are able to assess renal parameter called the effective renal plasma flow. clearance or function so that we can intervene and These parameters are all very important for your act in a timeous fashion. doctor. In patients with renal failure it also allows us to see What can I expect to happen? when dialysis will become necessary. In patients with kidney transplants it allows us to see when the Many things can affect kidney function that can transplant starts to deteriorate and oftentimes tell give spurious results. These include: us what is causing the deterioration.
    [Show full text]
  • Office Cystoscopy Urinary Tract Infection Rate and Cost Before And
    www.auajournals.org/journal/urpr Office Cystoscopy Urinary Tract Infection Rate and Cost before and after Implementing New Handling and Storage Practices Vincent Roth, Pedro Espino-Grosso, Carl H. Henriksen and Benjamin K. Canales* From the Department of Urology (VR, PE-G, CHH, BKC), University of Florida, Gainesville, Florida, Department of Surgery (VR, PE-G, BKC), Division of Urology, Malcom Randall Veterans Affairs Medical Center, Gainesville, Florida Abstract Abbreviations Introduction: Based on 2010 American Urological Association recommendations our practice and Acronyms fl transitioned from sterile to high level disinfection exible cystoscope reprocessing and from sterile AUA ¼ American to clean handling practices. We examined symptomatic urinary tract infection rate and cost before Urological Association and after policy implementation. GU ¼ genitourinary Methods: We retrospectively reviewed 30-day outcomes following 1,888 simple cystoscopy en- HLD ¼ high level counters that occurred from 2007 to 2010 (sterile, 905) and 2012 to 2015 (high level disinfection, disinfection 983) at the Malcom Randall Veterans Affairs Medical Center. We excluded veterans who had recent ¼ instrumentation, active or recent urinary tract infection, performed intermittent catheterization, or had SUNA Society of complicated cystoscopy (dilation, biopsy etc). Patient/procedural factors and cost were collected and Urologic Nurses and Associates compared between groups. UTI ¼ urinary tract Results: Both cohorts had similar age (mean 68 years), race (Caucasian, 82%), comorbidities infection (cancer history, 62%; diabetes mellitus, 36%; tobacco use, 24.5%), and cystoscopy procedural indications (cancer surveillance, 50%; hematuria, 34%). Urological complication rate was low between groups (1.43%) with no significant difference in symptomatic urinary tract infection events (0.99% sterile vs 0.51% high level disinfection, p¼0.29) or unplanned clinic/emergency department visits (0.66% sterile vs 0.71% high level disinfection, p¼0.91).
    [Show full text]
  • Advantages of Hybrid SPECT/CT Vs SPECT Alone Heather A
    The Open Medical Imaging Journal, 2008, 2, 67-79 67 Open Access Advantages of Hybrid SPECT/CT vs SPECT Alone Heather A. Jacene*,1, Sibyll Goetze1,2, Heena Patel1, Richard L. Wahl1 and Harvey A. Ziessman1 1Division of Nuclear Medicine, The Russell H. Morgan Department of Radiology and Radiological Science, Johns Hop- kins University, Baltimore, MD, USA 2Current Address: Department of Radiology, University of Alabama, Birmingham, AL, USA Abstract: We present our initial two year clinical experience with SPECT/CT, compare the interpretation to SPECT alone, provide illustrative cases, and review the published literature. Hybrid SPECT/CT has added clinical value over SPECT imaging alone primarily due to more precise anatomical lesion localization. After reading this report, the reader will appreciate the advantages of SPECT/CT imaging for clinical practice. We have reviewed SPECT/CT studies of 144 adult patients referred for various clinical indications in a busy nuclear medicine practice. The SPECT and fused SPECT/CT images were reviewed and interpreted separately to determine if addition of the fused CT images added in- cremental information, e.g., more definitive anatomic localization, more definitive diagnostic certainty, or changed final image interpretation compared to the SPECT images alone. Our analysis showed that SPECT/CT provided additional in- formation for image interpretation in 54% (78/144) of cases. In most of these (68/78), the CT data improved localization of abnormal and physiologic findings. Diagnostic certainty was improved in 34/144 cases (24%) and image interpretation was beneficially altered in 18/144 cases (13%). The fusion of anatomical and functional information by hybrid SPECT/CT positively impacts image interpretation and adds diagnostic value over SPECT alone.
    [Show full text]
  • Hemodialysis Central Venous Catheter Scrub-The-Hub Protocol
    Hemodialysis Central Venous Catheter Scrub-the-Hub Protocol This protocol outlines a suggested approach to preparing 4. Always handle the catheter hubs aseptically. Once catheter hubs prior to accessing the catheter for hemodialysis. disinfected, do not allow the catheter hubs to touch It is based on evidence where available and incorporates nonsterile surfaces. theoretical rationale when published evidence is unavailable. 5. Attach sterile syringe, unclamp the catheter, withdraw blood, and flush per facility protocol. Definitions: 6. Repeat for other limb (this might occur in parallel). Catheter refers to a central venous catheter (CVC) or a 7. Connect the ends of the blood lines to the catheter central line aseptically. Hub refers to the end of the CVC that connects to the 8. Remove gloves and perform hand hygiene. blood lines or cap Cap refers to a device that screws on to and occludes Disconnection Steps: the hub 1. Perform hand hygiene and don new clean gloves. Limb refers to the catheter portion that extends from the patient’s body to the hub 2. Clamp the catheter (Note: Always clamp the catheter before disconnecting. Never leave an uncapped catheter Blood lines refer to the arterial and venous ends of the unattended). extracorporeal circuit that connect the patient’s catheter 3. Disinfect the catheter hub before applying the new cap to the dialyzer using an appropriate antiseptic (see notes). a. (Optional) Disinfect the connection prior to disconnection. If this is done, use a separate antiseptic Catheter Connection and Disconnection pad for the subsequent disinfection of the hub. Steps: b. Disconnect the blood line from the catheter and Connection Steps disinfect the hub with a new antiseptic pad.
    [Show full text]
  • Diagnostic Performance of Contrast-Enhanced Ultrasound For
    www.nature.com/scientificreports OPEN Diagnostic performance of contrast‑enhanced ultrasound for acute pyelonephritis in children Hyun Joo Jung1, Moon Hyung Choi2, Ki Soo Pai1 & Hyun Gi Kim2,3* The objective of our study was to evaluate the performance of renal contrast‑enhanced ultrasound (CEUS) against the 99m-labeled dimercaptosuccinic acid (DMSA) scan and computed tomography (CT) in children for the diagnosis of acute pyelonephritis. We included children who underwent both renal CEUS and the DMSA scan or CT. A total of 33 children (21 males and 12 females, mean age 26 ± 36 months) were included. Using the DMSA scan as the reference standard, the sensitivity, specifcity, positive predictive value, and negative predictive value of CEUS was 86.8%, 71.4%, 80.5%, and 80.0%, respectively. When CT was used as the reference standard, the sensitivity, specifcity, positive predictive value, and negative predictive value of CEUS was 87.5%, 80.0%, 87.5%, and 80.0%, respectively. The diagnostic accuracy of CEUS for the diagnosis of acute pyelonephritis was 80.3% and 84.6% compared to the DMSA scan and CT, respectively. Inter-observer (kappa = 0.54) and intra-observer agreement (kappa = 0.59) for renal CEUS was moderate. In conclusion, CEUS had good diagnostic accuracy for diagnosing acute pyelonephritis with moderate inter‑ and intra‑observer agreement. As CEUS does not require radiation or sedation, it could play an important role in the future when diagnosing acute pyelonephritis in children. Urinary tract infection (UTI) is a common cause of illness with fever in children. It frequently develops in boys during their frst year of life and is more frequent in girls of older ages 1.
    [Show full text]
  • Radionuclides in Nephrourology, Part 2: Pitfalls and Diagnostic Applications
    Journal of Nuclear Medicine, published on March 3, 2014 as doi:10.2967/jnumed.113.133454 CONTINUING EDUCATION Radionuclides in Nephrourology, Part 2: Pitfalls and Diagnostic Applications Andrew T. Taylor Department of Radiology and Imaging Sciences, Emory University School of Medicine, Atlanta, Georgia Learning Objectives: On successful completion of this activity, participants should be able to describe (1) the common clinical indications of suspected obstruction and renovascular hypertension; (2) the status of radionuclide renal imaging in the evaluation of the transplanted kidney and the detection of infection; and (3) potential pitfalls. Financial Disclosure: This review was partially supported by a grant from the National Institutes of Health (NIH/NIDDK R37 DK38842). Andrew T. Taylor is entitled to a share of the royalties for the use of QuantEM software for processing MAG3 renal scans, which was licensed by Emory University to GE Healthcare in 1993. He and his coworkers have subsequently developed in-house, noncommercial software that was used in this study and could affect their financial status. The terms of this arrangement have been reviewed and approved by Emory University in accordance with its conflict-of-interest policies. The author of this article has indicated no other relevant relationships that could be perceived as a real or apparent conflict of interest. CME Credit: SNMMI is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to sponsor continuing education for physicians. SNMMI designates each JNM continuing education article for a maximum of 2.0 AMA PRA Category 1 Credits. Physicians should claim only credit commensurate with the extent of their participation in the activity.
    [Show full text]
  • Introducing PET/CT at AIMS, Kochi
    Nuclear medicine investigations use small amounts of FDA approved sterile radioactive materials for imaging. These investigations are safe, can be used in all age groups even extremes of age and are painless. Small amounts of radiopharmaceuticals are introduced into the body by injection, swallowing, or inhalation. These radiopharmaceuticals are substances, which are organ specific and get bound within a period of time to the organ and facilitate imaging. The amount of radiopharmaceutical used is carefully selected to provide the least amount of radiation exposure to the patient but ensure an accurate test. A special camera (PET, SPECT gamma camera) is then used to take pictures of your body. The camera detects the radiopharmaceutical in the organ, bone or tissue and forms images that provide data and information about the area in question. Nuclear medicine differs from an x-ray, ultrasound or other diagnostic test because it determines the presence of disease based on biological changes rather than changes in anatomy. Hence it helps in early detection of a disease much before other anatomical imaging modality picks up. GAMMA CAMERA (SPECT/CT) GAMMA CAMERA APPLICATIONS: Cardiac Applications: Coronary Artery Disease Measure Effectiveness of Bypass Surgery Measure Effectiveness of Therapy for Heart Failure Detect Heart Transplant Rejection Select Patients for Bypass or Angioplasty Identify Surgical Patients at High Risk for Heart Attacks Identify Right Heart Failure Measure Chemotherapy Cardiac Toxicity Evaluate Valvular Heart Disease Identify
    [Show full text]